AU2007350793A1 - Composition for promoting the maintenance and function of muscle-specific progenitor cells - Google Patents
Composition for promoting the maintenance and function of muscle-specific progenitor cells Download PDFInfo
- Publication number
- AU2007350793A1 AU2007350793A1 AU2007350793A AU2007350793A AU2007350793A1 AU 2007350793 A1 AU2007350793 A1 AU 2007350793A1 AU 2007350793 A AU2007350793 A AU 2007350793A AU 2007350793 A AU2007350793 A AU 2007350793A AU 2007350793 A1 AU2007350793 A1 AU 2007350793A1
- Authority
- AU
- Australia
- Prior art keywords
- muscle
- composition
- source
- creatine
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims description 51
- 210000003205 muscle Anatomy 0.000 title claims description 34
- 210000000130 stem cell Anatomy 0.000 title description 25
- 238000012423 maintenance Methods 0.000 title description 9
- 230000001737 promoting effect Effects 0.000 title description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 81
- 229960003624 creatine Drugs 0.000 claims description 37
- 239000006046 creatine Substances 0.000 claims description 37
- 210000001057 smooth muscle myoblast Anatomy 0.000 claims description 32
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 28
- 229920000855 Fucoidan Polymers 0.000 claims description 27
- 150000003408 sphingolipids Chemical class 0.000 claims description 19
- 206010028311 Muscle hypertrophy Diseases 0.000 claims description 18
- 230000012042 muscle hypertrophy Effects 0.000 claims description 18
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 15
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 15
- 235000021283 resveratrol Nutrition 0.000 claims description 15
- 229940016667 resveratrol Drugs 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 14
- 230000001114 myogenic effect Effects 0.000 claims description 13
- 239000002243 precursor Substances 0.000 claims description 13
- 230000004927 fusion Effects 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 5
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 230000000153 supplemental effect Effects 0.000 description 23
- 239000002245 particle Substances 0.000 description 20
- 235000015872 dietary supplement Nutrition 0.000 description 19
- 230000001939 inductive effect Effects 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 11
- 230000024977 response to activity Effects 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 239000007894 caplet Substances 0.000 description 10
- 210000002027 skeletal muscle Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 210000001087 myotubule Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000009469 supplementation Effects 0.000 description 8
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 6
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 6
- 240000001341 Reynoutria japonica Species 0.000 description 6
- 235000018167 Reynoutria japonica Nutrition 0.000 description 6
- 241000015177 Saccharina japonica Species 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 description 5
- 230000008827 biological function Effects 0.000 description 5
- 230000007910 cell fusion Effects 0.000 description 5
- 229960004826 creatine monohydrate Drugs 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000003800 Selectins Human genes 0.000 description 4
- 108090000184 Selectins Proteins 0.000 description 4
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 4
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000020411 cell activation Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- PBFDKFLAOSYLOL-DFWYDOINSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound NC(=N)N(C)CC([OH2+])=O.[O-]C(=O)[C@@H]1CCC(=O)N1 PBFDKFLAOSYLOL-DFWYDOINSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 241001261506 Undaria pinnatifida Species 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- -1 e.g. Substances 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical class OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000021268 myoblast fusion Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940043131 pyroglutamate Drugs 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000025175 skeletal muscle hypertrophy Effects 0.000 description 2
- 210000000419 skeletal muscle satellite cell Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- MBBREGJRSROLGD-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound NC(=N)N(C)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MBBREGJRSROLGD-UHFFFAOYSA-N 0.000 description 1
- DLNGCCQFGNSBOP-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.NC(=N)N(C)CC(O)=O DLNGCCQFGNSBOP-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 102000012000 CXCR4 Receptors Human genes 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical class [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 241000227647 Fucus vesiculosus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 102000008212 P-Selectin Human genes 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000008690 Pausinystalia yohimbe Nutrition 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000007646 directional migration Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MWZPENIJLUWBSY-VIFPVBQESA-N methyl L-tyrosinate Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWZPENIJLUWBSY-VIFPVBQESA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 230000013663 muscle adaptation Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 210000003130 muscle precursor cell Anatomy 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000004070 myogenic differentiation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000021135 plant-based food Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011667 skeletal muscle adaptation Effects 0.000 description 1
- 230000025185 skeletal muscle atrophy Effects 0.000 description 1
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 1
- 238000001374 small-angle light scattering Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004137 sphingolipid metabolism Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000007419 viral reactivation Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
WO 2008/122098 PCT/CA2007/000545 Composition for Promoting the Maintenance and Function of Muscle-Specific Pro2enitor Cells Field of the Invention 5 [001] The present invention is directed towards a composition and method for inducing muscle hypertrophy via satellite cells fusion to muscle fibres and for inducing a substantially simultaneous replenishment of myogenic precursor cells in response to exercise. Background of the Invention 10 [0021 Body composition, including muscle, is influenced both by genetic factors and environmental stimuli. Important environmental factors or stimuli which effect muscle metabolism include food intake and exercise (Rennie MJ. Body maintenance and repair: how food and exercise keep the musculoskeletal system in good shape. Exp Physiol. 2005 Jul;90(4):427-36). Gene and protein expression 15 patterns change in response to stimuli. This results in muscle adaptations such as muscle atrophy (loss) or muscle hypertrophy (gain). The determination of muscle loss or gain is the net effect of both positive and negative factors governing muscle development. [0031 'True' muscle hypertrophy can be defined as "as an increase in fiber 20 diameter without an apparent increase in the number of muscle fibers, accompanied by enhanced protein synthesis and augmented contractile force" (Sartorelli V, Fulco M. Molecular and cellular determinants of skeletal muscle atrophy and hypertrophy. Sci STKE. 2004 Jul 27;2004(244):rel 1). However, postnatal muscle growth is known to involve both myofiber hypertrophy and increased numbers of myonuclei - the 25 source of which are satellite cells (Olsen S, Aagaard P, Kadi F, Tufekovic G, Verney J, Olesen JL, Suetta C, Kjaer M. Creatine supplementation augments the increase in satellite cell and myonuclei number in human skeletal muscle induced by strength training. J Physiol. 2006 Jun 1;573(Pt 2):525-34). The growth in the size of muscles after birth is, in reality, a combination of an increase in the actual diameter of a given 30 muscle fiber and an increase in the number of mononuclei. [0041 Satellite cells are a small population of quiescent muscle precursor cells that occupy a "satellite" position immediately outside of muscle fibers (Mauro 1 WO 2008/122098 PCT/CA2007/000545 A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol. 1961 Feb;9:493 5). They are normally maintained in a quiescent state and become activated to fulfill roles of routine maintenance, repair and hypertrophy. Satellite cells are thought to be muscle-specific stem cells which are capable of producing large numbers of 5 differentiated progeny as well as being capable of self-renewal (Collins CA, Partridge TA. Self-renewal of the adult skeletal muscle satellite cell. Cell Cycle. 2005 Oct;4(10):1338-41). In order that satellite cells can fulfill their biological role, they must become activated, proliferate, differentiate and fuse to existing muscle cells (Anderson JE. The satellite cell as a companion in skeletal muscle plasticity: 10 currency, conveyance, clue, connector and colander. J Exp Biol. 2006 Jun;209(Pt 12):2276-92). In this way, multinucleate muscle fibers are maintained or increased in size in response to stimuli. [005] Activation of satellite cells is essential for their proper function and is defined as "an entry into GI from quiescence and mobilization" (Anderson JE, 15 Wozniak AC. Satellite cell activation on fibers: modeling events in vivo--an invited review. Can J Physiol Pharmacol. 2004 May;82(5):300-10). One of the main factors which has been associated with the activation of satellite cells is nitric oxide (NO) (Anderson JE, Wozniak AC. Satellite cell activation on fibers: modeling events in vivo--an invited review. Can J Physiol Pharmacol. 2004 May;82(5):300-10). NO is a 20 small, freely diffusible signaling molecule produced in muscle by neuronal NO synthase. NO release is regulated by stretching in skeletal muscle and is thought to be responsible for early satellite cell activation in response to muscle injury in proximal and distal muscle fibers (Anderson JE. A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells. Mol Biol Cell. 2000 25 May;11(5):1859-74). [0061 NO activity is largely controlled by regulating the enzymes responsible for synthesizing NO - Nitric Oxide Synthases (NOSs). All major nitric oxide synthase (NOS) isoforms and splice variants, including a muscle-specific splice variant, are expressed in the skeletal muscles of all mammals (Stamler JS, Meissner G. 30 Physiology of nitric oxide in skeletal muscle. Physiol Rev. 2001 Jan;81(1):209-237). Furthermore, the inner lining, or endothelium, of blood vessels uses NO to signal the surrounding smooth muscle to relax. This has the effect of dilating the artery thereby increasing blood flow in the affected region. 2 WO 2008/122098 PCT/CA2007/000545 [0071 NO has also been shown to play an important role in myoblast and satellite cell fusion (Pisconti A, Brunelli S, Di Padova M, De Palma C, Deponti D, Baesso S, Sartorelli V, Cossu G, Clementi E. Follistatin induction by nitric oxide through cyclic GMP: a tightly regulated signaling pathway that controls 5 myoblast fusion. J Cell Biol. 2006 Jan 16;172(2):233-44) thereby contributing to muscle maintenance and growth. Myoblast fusion is itself a complex process involving migration, recognition and adhesion, each involving several mechanisms and factors. [0081 If stem cells are to function properly, their pools must be maintained. 10 Therefore, a defining feature of stem cells is their ability of self-renewal in addition to being able to produce differentiated cells (Collins CA, Partridge TA. Self-renewal of the adult skeletal muscle satellite cell. Cell Cycle. 2005 Oct;4(10):1338-41). Research has shown that the pool of satellite cells is maintained not only by self renewal but also by contributions from the hematopoietic, i.e. blood, system 15 (Doyonnas R, LaBarge MA, Sacco A, Charlton C, Blau HM. Hematopoietic contribution to skeletal muscle regeneration by myelomonocytic precursors. Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13507-12). [0091 In the case where hematopoietic stem cells contribute to muscle maintenance, the cells must migrate to the area at which they are required for repair or 20 maintenance. This directed migration of stem/progenitor cells is termed 'mobilization'. A main mechanism for the mobilization of stem cells is through the release of signaling molecules at the site of the stem cell requirement wherein the stem cells express the corresponding cell surface receptors (Papayannopoulou T. Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. 25 Blood. 2004 Mar 1;103(5):1580-5). An important receptor-ligand system for the relationship between the hematopoietic and muscle systems is the CXCR-4 receptor and the secreted chemokine, SDF-1 (Ratajczak MZ, Majka M, Kucia M, Drukala J, Pietrzkowski Z, Peiper S, Janowska-Wieczorek A Expression of functional CXCR4 by muscle satellite cells and secretion of SDF-1 by muscle-derived fibroblasts is 30 associated with the presence of both muscle progenitors in bone marrow and hematopoietic stem/progenitor cells in muscles. Stem Cells. 2003;21(3):363-71). [0010] The foregoing disclosure describes a composition and method for stimulating the aforementioned for purposes of muscle hypertrophy in a mammal. 3 WO 2008/122098 PCT/CA2007/000545 Summary of the Invention 100111 The present invention comprises, in accordance with an embodiment thereof, the administration, to a mammal, of a composition comprising at least creatine or pharmaceutically acceptable derivatives of creatine such as salts and esters 5 of creatine and a source of fucoidan, to induce muscle hypertrophy via satellite cell fusion to muscle fibres and to provide substantially coincident support for the replenishment of myogenic precursor cells in response to exercise. Detailed Description of the Invention [0012] In the following description, for the purposes of explanations, 10 numerous specific details are set forth in order to provide a thorough understanding of the present invention. It will be apparent, however, to one of ordinary skill in the art that the present invention may be practiced without these specific details. [00131 The present invention is directed towards inducing muscle hypertrophy via satellite cell fusion to muscle fibres and provide substantially coincident support 15 for the replenishment of myogenic precursor cells in response to exercise. The composition and method of the present invention accomplishes said support by encouraging multiple distinct aspects of muscle-specific progenitor cell biology. [0014] As used herein, the term "muscle-specific progenitor cell" refers to any undifferentiated cell that is, or will be, at any time, capable of differentiating into any 20 cell type which contributes to mature, functional adult skeletal muscle. This, for the purposes of the present disclosure, includes satellite cells and any other multi-potent cells such as hematopoietic stem cells which have the potential to contribute to skeletal muscle hypertrophy and growth, development or maintenance. It is herein understood that, despite a lack of consensus regarding nomenclature, there exists a 25 continuum of cell types that lie between a classical pluripotent 'embryonic stem cell' capable of giving rise to all cell types on one extreme and a terminally-differentiated cell on the other extreme. It is herein understood that a number of undifferentiated cell types having increasingly limited developmental potential progressing from an embryonic stem cell toward a terminally-differentiated cell exist between said 30 extremes. Furthermore, it is herein understood that such undifferentiated cells with limited, yet still multiple, developmental possibilities are generally termed 'tissue 4 WO 2008/122098 PCT/CA2007/000545 specific stem cells'. However, undifferentiated cells with only one developmental possibility are generally termed 'progenitor cells'. [0015] Ingredients of the present composition may also be fine-milled in order to improve the immediacy of absorption, and thus the rate of bioavailability upon 5 consumption by an individual. The fine-milling techniques and the immediacy of absorption employed in the present invention are disclosed in U.S. Patent Application No. 11/709,526, entitled "Method For Increasing The Rate And Consistency Of Bioavailability Of Supplemental Dietary Ingredients" and U.S. Patent Application No. 11/709,525, entitled "Method for a Supplemental Dietary Composition Having a 10 Multi-Phase Dissolution Profile," both herein incorporated fully by reference. Briefly, rate of bioavailability is increased via a narrowing of particle size range and a concomitant reduction in the average particle size, improving the immediacy of absorption of said supplemental dietary ingredient. Furthermore, the consistency of dissolution, and thus the absorption of orally administered supplemental dietary 15 ingredients, is improved by the fine-milled process. [00161 As used herein, the term "fine-milled" and/or "fine-milling" refers to the process of micronization. Micronization is a mechanical process that involves the application of force to a particle, thereby resulting in a reduction in the size of the particle. The force, in the case of micronization may be applied in any manner such 20 as, e.g., the collision of particles at high rates of speed, grinding, or by an air-jet micronizer. In a preferred embodiment, fine-milled particles are obtained by jet milling with nitrogen and compressed air. [00171 As used herein, the term "particle size" refers to the diameter of the particle. The term "average particle size" means that at least 50% of the particles in a 25 sample will have the specified particle size. Preferably, at least 80% of the particles in a sample will have the specified particle size, and more preferably, at least 90% of the particles in a given sample will have the specified particle size. For the purposes of the present invention, the preferred particle size range for fine-milled particles is between 2 and 50 microns. 30 [00181 The size of a particle can be determined by any of the methods known within the art. Methods for particle size determination which may be employed are, for example, sieves, sedimentation, electrozone sensing (Coulter counter), 5 WO 2008/122098 PCT/CA2007/000545 microscopy, and/or Low Angle Laser Light Scattering. The preferred methods for the particle size determination of the present invention are the methods which are most commonly used in the pharmaceutical industry, such as laser diffraction, e.g., via light scattering Coulter Delsa 440SX. 5 [0019] The fine-milling process may be employed in the processing of one or more of the ingredients of the present invention in the dosage forms of tablets, e.g., immediate-release film coated, modified-release and fast-dissolving; capsules, e.g., immediate-release and modified-release; liquid dispersions; powders; drink mixes, etc. 10 Creatine 100201 Creatine use has been thoroughly studied and is well-established as a beneficial dietary supplement for replenishing energy stores in working muscle cells (Greenhaff PL, Bodin K, Soderlund K, Hultman E. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. Am J Physiol. 1994 15 May;266(5 Pt 1):E725-30). The resultant increase in muscular energy stores from creatine supplementation in an individual, combined with physical exercise leads to increased strength, and a reduction in fatigue resulting from high-intensity exercise (Greenhaff PL, Casey A, Short AH, Harris R, Soderlund K, Hultman E. Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal 20 voluntary exercise in man. Clin Sci (Lond). 1993 May;84(5):565-71) as well as increasing muscle growth (Volek JS, Duncan ND, Mazzetti SA, Staron RS, Putukian M, Gomez AL, Pearson DR, Fink WJ, Kraemer WJ. Performance and muscle fiber adaptations to creatine supplementation and heavy resistance training. Med Sci Sports Exerc. 1999 Aug;31(8):1147-56). 25 [0021] More recently however, creatine supplementation has been shown to augment the increase in satellite cell numbers in response to exercise (Olsen S, Aagaard P, Kadi F, Tufekovic G, Verney J, Olesen JL, Suetta C, Kjaer M. Creatine supplementation augments the increase in satellite cell and myonuclei number in human skeletal muscle induced by strength training. J Physiol. 2006 Jun 1;573(Pt 30 2):525-34). Furthermore, it was suggested by the results of Olsen et al., that the rate of fusion of satellite cells was also increased in response to creatine supplementation and exercise, adding to an observed increase in the size of muscle fibers. 6 WO 2008/122098 PCT/CA2007/000545 [00221 In various embodiments of the present invention, which are set forth in greater detail in Examples 1 to 4 below, the supplemental composition comprises creatine or derivatives thereof. A serving of the supplemental composition comprises from about 1.00 g to about 10.00 g of creatine or derivatives thereof. The preferred 5 dosage of a serving of the supplemental composition of the present invention comprises about 3.50 g of creatine or pharmaceutically acceptable derivatives of creatine such as salts and esters of creatine. [00231 For example, the creatine may be present in various embodiments of the present invention as creatine salts of malate, maleate, fumarate, tartrate, citrate, 10 succinate, pyruvate, pyroglutamate, glutamate or any other pharmaceutically acceptable salt as known in the art. [0024] Additionally or alternatively, the creatine may be present in various embodiments of the present invention as creatine esters of phosphate, sulphate or any other pharmaceutically acceptable esters as known in the art. 15 [00251 The present invention, as set forth in greater detail in Example 4 below, may further comprise creatine pyroglutamate as a pharmaceutically acceptable derivative of creatine. A serving of the supplemental composition may comprise from about 0.005 g to about 0.10 g of creatine pryoglutamate. The preferred dosage of a serving of the supplemental composition comprises about 0.01 g of creatine 20 pyroglutamate. [0026] The present invention may further comprise at least a portion of the creatine or pharmaceutically acceptable salts or esters thereof in a fine-milled format. In various embodiments of the present invention, the supplemental composition comprises fine-milled creatine or pharmaceutically acceptable salts or esters of said 25 creatine. A serving of the supplemental composition comprises from about 0.005 g to about 0.05 g of fine-milled creatine or pharmaceutically acceptable salts or esters of said creatine. The preferred dosage of a serving of the supplemental composition comprises about 0.02 g of fine-milled creatine or pharmaceutically acceptable salts or esters of said creatine. 30 Fucoidan [0027] Fucoidans are naturally-occurring sulfated sugar polymers. They are constituents of edible seaweed and have been consumed by humans for centuries. 7 WO 2008/122098 PCT/CA2007/000545 The specific type of fucoidan differs dependent upon the source. Brown seaweed, in particular, is a source of branched-chain Fucoidans and several species have been used experimentally as a source of Fucoidans including Fucus vesiculosus, Undaria pinnatifida and Laminaria japonica. One of the main and earliest mechanisms 5 elucidated for the activity of Fucoidans has been the binding with L- and P-selectin, members of a family of cell surface receptors involved in the inflammatory response. The selectins mediate the binding and adhesion of cells expressing the selectins to other cells such as those on the endothelium upon cytokine activation (Bevilacqua MP, Nelson RM. Selectins. J Clin Invest. 1993 Feb;91(2):379-87). 10 [00281 A number of potential beneficial uses have been suggested for Fucoidan (Berteau 0, Mulloy B. Sulfated fucans, fresh perspectives: structures, functions, and biological properties of sulfated fucans and an overview of enzymes active toward this class of polysaccharide. Glycobiology. 2003 Jun;13(6):29R-40R). Fucoidan has been shown to have immunomodulating effects by stimulating 15 lymphocytes and macrophages (Choi EM, Kim AJ, Kim YO, Hwang JK. Immunomodulating activity of arabinogalactan and fucoidan in vitro. J Med Food. 2005 Winter;8(4):446-53). As well, Herpes virus reactivation can be inhibited by treatment with Fucoidan (Cooper R, Dragar C, Elliot K, Fitton JH, Godwin J, Thompson K. GFS, a preparation of Tasmanian Undaria pinnatifida is associated with 20 healing and inhibition of reactivation of Herpes. BMC Complement Altern Med. 2002 Nov 20;2:11). Importantly, orally administered Fucoidan in humans has been shown to increase the number of CXCR-4-expressing stem cells which can replenish the pool of satellite cells (Irhimeh MR et al. Fucoidan and CXCR4+ hemopoietic progenitor stem cell population, 2004, The Sydney Convention Centre North, Darling Harbour, 25 Australian StemCell Centre). Furthermore, fucoidan can induce the mobilization of these stem cells to muscles (Sweeney EA, Priestley GV, Nakamoto B, Collins RG, Beaudet AL, Papayannopoulou T. Mobilization of stem/progenitor cells by sulfated polysaccharides does not require selectin presence. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6544-9). This effect is most likely due to the observed effect of 30 increasing SDF-1 plasma levels (Sweeney EA, Lortat-Jacob H, Priestley GV, Nakamoto B, Papayannopoulou T. Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood. 2002 Jan 1;99(1):44-51). 8 WO 2008/122098 PCT/CA2007/000545 [0029] In a preferred embodiment of the present invention, the supplemental composition comprises fucoidan. A serving of the supplemental composition comprises from about 0.01 g to about 0.1 g of fucoidan. The preferred dosage of a serving of the supplemental composition of the present invention comprises about 5 0.024 g of fucoidan. [0030] In various embodiments of the present invention, which are set forth in greater detail in Examples 1 to 4 below, the supplemental composition comprises Laminariajaponica extract as a source of fucoidan. Sphinoglipids 10 [0031] Sphingolipids are important constituents of eukaryotic organisms. Complex sphingolipids and their metabolic products are highly bioactive molecules which are involved in the regulation of many important biological functions including cell growth, differentiation and apoptosis (Vesper H, Schmelz EM, Nikolova Karakashian MN, Dillehay DL, Lynch DV, Merrill AH Jr. Sphingolipids in food and 15 the emerging importance of sphingolipids to nutrition. J Nutr. 1999 Jul;129(7):1239 50). Sphingolipid metabolism and biological function can be modulated by dietary intake of sphingolipids. Supplying supplemental sphingolipids promotes the synthesis of sphingosine 1-phosphate. [00321 Sphingosine 1-phosphate is a bioactive sphingolipid metabolite that 20 has been shown to regulate a number of important biological functions including satellite cell activation (Nagata Y, Partridge TA, Matsuda R, Zammit PS. Entry of muscle satellite cells into the cell cycle requires sphingolipid signaling. J Cell Biol. 2006 Jul 17;174(2):245-53) and myogenic differentiation (Donati C, Meacci E, Nuti F, Becciolini L, Farnararo M, Bruni P. Sphingosine 1-phosphate regulates myogenic 25 differentiation: a major role for S1P2 receptor. FASEB J. 2005 Mar;19(3):449-51), both of which are processes important for increasing muscle hypertrophy. [0033] In embodiments of the present invention, which are set forth in greater detail in Examples 2 to 4 below, the supplemental composition comprises a source of sphingolipids. A serving of the supplemental composition of the present invention 30 comprises from about 0.005 g to about 0.05 g of a source of sphingolipids. The preferred dosage of a serving of the supplemental composition of the present invention comprises about 0.014 g of a source of sphingolipids. 9 WO 2008/122098 PCT/CA2007/000545 Resveratrol [00341 Resveratrol is a polyphenol found in many plant sources, most notably in grape skins, grape juice and red wine. One of the most abundant sources is from the roots of Polygonum cuspidatum. In plants, the biological function of resveratrol is 5 as an antibiotic to fight infection. However, as a component of the diet, either as a constituent of plant-based foods or as a nutritional supplement, resveratrol has been reported to confer many health benefits. The main beneficial function of polyphenols from plant sources is generally attributed to antioxidant activity. However, resveratrol has been shown to increase NO production by tissue-specific induction of 10 NOSs (Das S, Alagappan VK, Bagchi D, Sharma HS, Maulik N, Das DK. Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Vascul Pharmacol. 2005 Apr-May;42(5-6):281-9 Abstract). [0035] In various embodiments of the present invention, which are set forth in 15 greater detail in Examples 3 and 4 below, the supplemental composition of the present invention comprises Polygonum cuspidatum as a source of resveratrol. A serving of the supplemental composition of the present invention comprises from about 0.001 g to about 0.01 g of Polygonum cuspidatum as a source of resveratrol. The preferred dosage of a serving of the supplemental composition of the present invention 20 comprises about 0.004 g of Polygonum cuspidatum as a source of resveratrol. [0036] In a preferred embodiment of the present invention, the composition of the present invention comprises at least creatine or pharmaceutically acceptable derivatives of creatine such as salts and esters of creatine and a source of fucoidan. [0037] In another embodiment of the present invention, the composition of the 25 present invention comprises creatine or pharmaceutically acceptable derivatives of creatine such as salts and esters of creatine, a source of fucoidan and a source of sphingolipids. [00381 In yet another embodiment of the present invention, the composition of the present invention comprises creatine or pharmaceutically acceptable derivatives of 30 creatine such as salts and esters of creatine, a source of fucoidan, a source of sphinoglipids and a source of resveratrol. 10 WO 2008/122098 PCT/CA2007/000545 [0039] The compositions of the present invention may also comprise, in addition to the aforementioned constituents, any number of amino acids in sufficient quantities to be effective in inducing muscle hypertrophy, or salts or esters of said amino acids. For example, proteins, such as whey protein, casein protein, milk 5 proteins, or soy protein, may further be included in the compositions of the present invention in quantities effective to induce muscle hypertrophy. Amino acids and proteins are well known in the art to aid in the generation and repair of muscle protein. [0040] Not wishing to be bound by theory, it is believed that the various 10 components of the present invention will act via multiple, distinct biological pathways to aid in the maintenance and function of myogenic precursor cells in repair and growth of skeletal muscle. The composition of the present invention, when used in conjunction with the method provided herein, induces muscle hypertrophy via satellite cells fusion to muscle fibres and induces the substantially simultaneous 15 replenishment of myogenic precursor cell in response to exercise. [0041] Additionally, by way of ingestion of the composition of the present invention, a method for enhancing the effectiveness of the immune system in an individual is provided. The method of the present invention comprises at least the step of administering to an individual a therapeutically effective and acceptable 20 amount of the composition of the present invention. [0042] According to additional methods, the compositions of the present invention may be administered to a mammal via any therapeutically acceptable format. For example, the compositions of the present invention may be administered to a mammal intravenously, intramuscularly, or interperitoneally as routes of 25 administration distinct from the aforementioned oral method. These instantly disclosed routes of administration may also be combined with an oral administration of the composition of the present invention as an additional method of administration to a mammal. 100431 According to various embodiments of the present invention, the 30 nutritional supplement may be consumed in any form. For instance, the dosage form of the nutritional supplement may be provided as, e.g., a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a liquid capsule, a 11 WO 2008/122098 PCT/CA2007/000545 tablet, a caplet, or as a dietary gel. The preferred dosage forms of the present invention are as a caplet or as a liquid capsule. The present composition may also be provided in various time-release formats, e.g. a slow-release format, a quick-release format, or a phase-release format, as are known in the art as well. 5 [00441 Furthermore, the dosage form of the nutritional supplement may be provided in accordance with customary processing techniques for herbal and nutritional supplements in any of the forms mentioned above. Additionally, the nutritional supplement set forth in the example embodiments herein may contain any appropriate number and type of excipients, as is well known in the art. 10 [0045] The present nutritional composition or those similarly envisioned by one of skill in the art, may be utilized in methods to support the biological function of muscle-specific progenitor cells required for skeletal muscle recovery and growth in response to exercise. Specifically, the present compositions and method disclosed herein are provided to induce muscle hypertrophy via satellite cell fusion to muscle 15 fibres and induce a substantially coincident replenishment of myogenic precursor cell in response to exercise. [00461 Although the following examples illustrates the practice of the present invention in several of its embodiments, the examples should not be construed as limiting the scope of the invention. Other embodiments will be apparent to one of 20 skill in the art from consideration of the specifications and examples. 12 WO 2008/122098 PCT/CA2007/000545 Examples Example 1 [0047] A nutritional supplement for inducing muscle hypertrophy via satellite cell fusion to muscle fibres and inducing a substantially simultaneous replenishment 5 of myogenic precursor cell in response to exercise is provided. The nutritional supplement is in the form of caplets. One serving of the nutritional supplement is 7 caplets and each serving comprises: [0048] about 3.5 g of creatine monohydrate (fine-milled), and about 0.024 g of Laminariajaponica extract (standardized to 85% fucoidan). 10 Example 2 [00491 A nutritional supplement for inducing muscle hypertrophy via satellite cells fusion to muscle fibres and inducing a substantially simultaneous replenishment of myogenic precursor cell in response to exercise is provided. The nutritional supplement is in the form of caplets. One serving of the nutritional supplement is 7 15 caplets and each serving comprises: [0050] about 3.5 g of creatine monohydrate (fine-milled), about 0.024 g of Laminaria japonica extract (standardized to 85% fucoidan), and about 0.0145 g of soy/milk sphingolipids. Example 3 20 [0051] A nutritional supplement for inducing muscle hypertrophy via satellite cells fusion to muscle fibres and inducing a substantially simultaneous replenishment of myogenic precursor cell in response to exercise is provided. The nutritional supplement is in the form of caplets. One serving of the nutritional supplement is 7 caplets and each serving comprises: 25 [0052] about 3.5 g of creatine monohydrate (fine-milled), about 0.024 g of Laminaria japonica extract (standardized to 85% fucoidan), about 0.0145 g of soy/milk sphingolipids, and about 0.004 g of Polygonum cuspidatum,. Example 4 10053] A nutritional supplement for inducing muscle hypertrophy via satellite 30 cells fusion to muscle fibres and inducing a substantially simultaneous replenishment 13 WO 2008/122098 PCT/CA2007/000545 of myogenic precursor cell in response to exercise is provided. The nutritional supplement is in the form of caplets. One serving of the nutritional supplement is 7 caplets and each serving comprises: [00541 about 2.00 g of creatine monohydrate (fine-milled), about 0.02 g of 5 creatine monohydrate (nanodiffuse), about 0.01 g of creatine pyroglutamate, about 1.30 g of creatine citrate, about 0.001 g of creatine malate, about 0.02 g of creatine pyruvate, about 0.024 g of Laminaria japonica extract (standardized to 85% fucoidan), about 0.0145 g of soy/milk sphingolipids, about 0.004 g of Polygonum cuspidatum, about 0.05 g of L-glycine ethyl ester, about 2.9 g of L-tyrosine, about 10 0.001 g of L-tyrosine methyl ester, and about 0.002 g of Yohimbe. Extensions and Alternatives [00551 In the foregoing specification, the invention has been described with specific embodiments thereof. However, it will be evident that various modifications 15 and changes may be made thereto without departing from the broader spirit and scope of the invention. 14
Claims (11)
1. A composition comprising creatine or derivatives thereof and a source of fucoidan in amounts effective to induce muscle hypertrophy and to induce a 5 substantially simultaneous replenishment of myogenic precursor cells in a mammal.
2. The composition of claim 1, wherein muscle hypertrophy is induced via satellite cells fusion to muscle fibres in a mammal.
3. The composition of claim 1, further comprising a source of sphingolipids.
4. The composition of claim 3, wherein the source of sphingolipids is provided in 10 an amount effective to promote the synthesis of sphingosine 1-phosphate in a mammal.
5. The composition of claim 3, further comprising a source of resveratrol.
6. The composition of claim 5, wherein the source of resveratrol is provided in an amount effective to increase the production of nitric oxide in a mammal. 15
7. A method comprising at least the step of administering to a mammal a composition comprising creatine or derivative thereof and a source of fucoidan wherein said composition induces muscle hypertrophy and substantially simultaneously induces a replenishment of myogenic precursor cells in said mammal in response to physical exercise. 20
8. The method of claim 7, wherein the composition further comprises a source of sphingolipids.
9. The method of claim 8, wherein the source of sphingolipids promote the synthesis of sphingosine 1-phosphate in the mammal.
10. The method of claim 7, wherein the composition further comprises a source of 25 resveratrol.
11. The method of claim 10, wherein the source of resveratrol increases the production of nitric oxide in the mammal. 15
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA2007/000545 WO2008122098A1 (en) | 2007-04-04 | 2007-04-04 | Composition for promoting the maintenance and function of muscle-specific progenitor cells |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2007350793A1 true AU2007350793A1 (en) | 2008-10-16 |
Family
ID=39830423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007350793A Abandoned AU2007350793A1 (en) | 2007-04-04 | 2007-04-04 | Composition for promoting the maintenance and function of muscle-specific progenitor cells |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2142195A4 (en) |
AU (1) | AU2007350793A1 (en) |
CA (1) | CA2682589A1 (en) |
WO (1) | WO2008122098A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2381951B1 (en) * | 2009-01-28 | 2015-12-23 | Life Science Nutrition AS | Compositions and methods of treating viral infections |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005110448A2 (en) * | 2004-05-07 | 2005-11-24 | Thermo Formulations Ltd. | Nutritional composition for increasing creatine uptake in skeletal muscle |
US20070020358A1 (en) * | 2005-03-18 | 2007-01-25 | Mower Thomas E | Sports drink concentrate |
-
2007
- 2007-04-04 WO PCT/CA2007/000545 patent/WO2008122098A1/en active Application Filing
- 2007-04-04 AU AU2007350793A patent/AU2007350793A1/en not_active Abandoned
- 2007-04-04 CA CA002682589A patent/CA2682589A1/en not_active Abandoned
- 2007-04-04 EP EP07719475A patent/EP2142195A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2008122098A1 (en) | 2008-10-16 |
EP2142195A4 (en) | 2011-10-12 |
EP2142195A1 (en) | 2010-01-13 |
CA2682589A1 (en) | 2008-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3130336A1 (en) | Food and/or nutraceutical composition containing pea | |
ES2458353T3 (en) | Preparation comprising amino acids and plants and their activity in alcohol detoxification and in the treatment of migraine | |
US5840715A (en) | Dietary regimen of nutritional supplements for relief of symptoms of arthritis | |
AU2016375177A1 (en) | Compositions comprising nicotinamide riboside and a urolithin | |
JP2013515718A (en) | Low calorie high protein nutritional composition for stimulating muscle protein synthesis | |
AU2017270131A1 (en) | Nutritional composition for treating or preventing impaired mobility | |
EP0951909B1 (en) | Combination composition comprising a L-carnitine or an alkanoyl-L-carnitine, a glycosaminoglycan and/or constituent thereof | |
EP0855908B1 (en) | Dietary regimen of nutritional supplements for relief of symptoms of arthritis | |
US20110160136A1 (en) | Polyphenols for the treatment of cartilage disorders | |
JP2018532769A (en) | Composition comprising urolithin compound | |
EP2859896B1 (en) | Pharmaceutical compositions for the treatment of muscular disorders | |
JPWO2019230233A1 (en) | Devil's Claw Extract, various compositions containing it, and method for producing Devil's Claw Extract | |
US20110028400A1 (en) | Sulfated unsaturated disaccharidic chondroitin sulfate in connective tissue protection and repair | |
CA3226805A1 (en) | Paraxanthine-based caffeine substitute compositions and method of use thereof in slow caffeine metabolizers | |
US20080249063A1 (en) | Composition for promoting the maintenance and function of muscle-specific progenitor cells | |
AU2007350793A1 (en) | Composition for promoting the maintenance and function of muscle-specific progenitor cells | |
US20060135444A1 (en) | Combination of flavonoid and procyanidin for the reduction of the mammalian appetite | |
JP7168477B2 (en) | Food composition and osteoblast differentiation promoter | |
DOWNEY | FISH OIL | |
JP2006104080A (en) | Composition and health food having prophylactic or therapeutic effect on gout and bloodstream disorder caused by uric acid | |
AU2019305075A1 (en) | Nutritional compositions for enhancement of muscle performance | |
OSTEOMALACIA et al. | Nutrients Applied to Injury Rehabilitation and Sports Medicine 223 | |
WO2013108263A1 (en) | Pharmaceutical formulation to reduce inflammation of bones and joint friction with improved cartilage quality |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE APPLICANT NAME FROM IOVATE T & P INC. TO IOVATE T. & P. INC. |
|
PC1 | Assignment before grant (sect. 113) |
Owner name: NORTHERN INNOVATIONS AND FORMULATIONS CORP. Free format text: FORMER APPLICANT(S): IOVATE T. & P. INC. |
|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |